Nuclide Therapeutics Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—4

Registered number: 15734758

		31 March 2026		31 March 2025
	Notes	£	£	£	£
FIXED ASSETS
Tangible Assets	4		6,564		-

			6,564		-
CURRENT ASSETS
Debtors	5	9,038		-
Cash at bank and in hand		1,933,182		26

		1,942,220		26
Creditors: Amounts Falling Due Within One Year	6	(8,040 )		(199 )

NET CURRENT ASSETS (LIABILITIES)			1,934,180		(173 )

TOTAL ASSETS LESS CURRENT LIABILITIES			1,940,744		(173 )

NET ASSETS/(LIABILITIES)			1,940,744		(173 )

CAPITAL AND RESERVES
Called up share capital	7		1		1
Share premium account			2,500,000		-
Profit and Loss Account			(559,257 )		(174 )

SHAREHOLDERS' FUNDS			1,940,744		(173)

Page 1

Page 2

Nuclide Therapeutics Ltd

Balance Sheet (continued)

As At 31 March 2026

For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Dr Sofia Dos Santos

Director

3 June 2026

The notes on pages 3 to 4 form part of these financial statements.

1. General Information

Nuclide Therapeutics Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 15734758 . The registered office is 124 City Road, London, EC1V 2NX.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment

3 years straight line

2.4. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 3 (2025: NIL)

4. Tangible Assets

	Computer Equipment
	£
Cost
As at 1 April 2025	-
Additions	8,439

As at 31 March 2026	8,439

Depreciation
As at 1 April 2025	-
Provided during the period	1,875

As at 31 March 2026	1,875

...CONTINUED

Page 3

Page 4

Nuclide Therapeutics Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2026

Net Book Value
As at 31 March 2026	6,564

As at 1 April 2025	-

5. Debtors

	31 March 2026	31 March 2025
	£	£
Due within one year
Other debtors	4,666	-
Net wages	4,372	-

	9,038	-

6. Creditors: Amounts Falling Due Within One Year

	31 March 2026	31 March 2025
	£	£
Other creditors	379	199
Taxation and social security	7,661	-

	8,040	199

7. Share Capital

	31 March 2026	31 March 2025
	£	£
Allotted, Called up and fully paid	1	1

Page 4